The future of ADCs looks promising, with ongoing research focused on: - Improving Linkers: Developing more stable and cleavable linkers to ensure efficient drug release within cancer cells. - Novel Payloads: Exploring new cytotoxic drugs with different mechanisms of action to overcome resistance. - Targeting New Antigens: Identifying novel and more specific antigens to expand the range of cancers treatable by ADCs. - Combination Therapies: Combining ADCs with other treatments, such as immune checkpoint inhibitors, to enhance therapeutic efficacy.
